Xequel Bio acquired an exclusive, worldwide license from the Medical University of South Carolina (MUSC) for all fields of use for our pioneering technology platform, aCT1. Our strong partnership with MUSC has forged the way for an incredible breadth and depth of research into aCT1 and its varied potential applications.
Research Grant Support
National Institutes of Health (NIH)
Department of Defense (DOD)
Biomedical Advanced Research and Development Authority (BARDA)
Xequel Bio is honored to collaborate with top tier research institutions to further the understanding and utilization of our proprietary aCT1 platform.